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New palladacyclopentadienyl complexes with bis-N-heterocyclic carbenes as spectator ligands have been
synthesized and exhaustively characterized. The crystal structure of complex 1a has been also deter-
mined by X-ray diffraction analysis. Their in vitro cytotoxicity and that of other palladacyclopentadienyl
derivatives coordinating different ancillary ligands has been determined against different cancer cell
lines. Many complexes have shown an antiproliferative activity toward tumor cells often deﬁnitely better
than cisplatin, whereas they have resulted practically inactive against the non-cancer MRC-5 cell line.
The mechanism of action of bis-NHC derivative 1a, particularly active against ovarian cancer cell lines
was studied in depth. Through a longitudinally analysis, it is shown that compound 1a induces apoptosis
via DNA damage and release of cytochrome C. We propose compound 1a as a powerful and speciﬁc drug
for the therapy of a deadly disease such as high grade serous ovarian cancer.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Since the discovery of cisplatin, a successful chemotherapeutic
drug approved by the FDA in 1978, a great number of platinum
complexes has been synthesized in hopes of reducing the side ef-
fects and the resistance mechanisms observed for some types of
tumors treated with cisplatin-based therapies [1].
Unfortunately, the second and third generation of platinum
chemotherapy drugs (i.e. carboplatin and oxaliplatin) have retained
some contraindications and moreover have proven in many cases
inactive or poorly active against cisplatin-resistant neoplasms [2].
For this reason, many research groups have focused their efforts on
ﬁnding new anticancer agents based on other transition metals [3].
Among the non-platinum derivatives, palladium complexes have
received an increasing attention for their good antiproliferative
effects, generally associated with different mechanisms of action as
compared to cisplatin and analogues. Furthermore, palladium
compounds have the advantage of being generally less expensiveserved.and more water-soluble than platinum homologues [4]. On the
other hand, a potential limitation is represented by their high rate
of hydrolysis, and the elevated lability of the coordinated ligands is
often associated with the sequestration of the metal by bio-
molecules containing soft donating atoms, mainly proteins and
derivatives [4,5]. This feature increases their general toxicity and
reduces the possibility that the drug could selectively reach the
predicted target [6]. This critical point suggests that a careful choice
of the ligands coordinating the metal centre may play a key role in
the design of palladium anticancer compounds. In this regard, it has
recently been shown that ligands ﬁrmly anchored to palladium
reduce or eliminate the hydrolysis problems [7].
N-heterocyclic carbenes (NHCs) represent a class of ligands able
to satisfy this important requirement [8] and thus, beside homo-
geneous catalysis [9], have found numerous applications in the
biomedical ﬁeld, mostly in the synthesis of antitumor [7,10] and
antimicrobial compounds [11].
The synthesis of Pd (II) complexes stabilized by NHCs deriving
from natural xanthine bases and containing the h3-allyl or palla-
dacyclopentadienyl organometallic fragments has recently been
reported by our group [12]. These works were justiﬁed by the fact
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was practically unexplored, whereas their reactivity and applica-
tions in the ﬁeld of catalysis are well known [13,14].
The antiproliferative and proapoptotic activity tests carried out
on human ovarian cancer lines have shown that some of the syn-
thesized complexes exhibit higher activity than cisplatin both on
cisplatin-sensitive and cisplatin-resistant lines. At the same time,
these compounds are poorly active or inactive towards normal cells
(ﬁbroblasts).
Encouraged by these ﬁrst results, in the present paper we pro-
pose an in-depth study of the antitumor activity of the palladacy-
clopentadienyl complexes reported in Chart 1 against different
types of human cancer cells.
The palladacyclopentadienyl framework is a particularly stable
structure as proved by numerous studies on the reactivity of
complexes containing this organometallic function, carried out by
our research group [15]. In particular, it was shown that these
species are quickly attacked only by strong oxidants such as halo-
gens, which are not usually present in biological environment.
Therefore, if the palladacyclopentadienyl motif is combined with
strong spectator ligands may be possible to obtain very stable
complexes that could behave like structural compounds in the
cellular environment.
In a recent paper published by Che and co-workers, cyclo-
metallated Pd (II) complexes with different spectator ligands have
been reported. For these complexes, the antiproliferative activity
has been found to depend strongly on the type of spectator ligand.
The most effective complexes are those coordinating a N-hetero-
cyclic carbene ligand; they are stable in the presence of biological
thiols (i.e. glutathione) and act as structural compounds mainly by
altering the mitochondrial membrane of the cancer cells [7e].
On the basis of these facts, we report the synthesis of yet un-
published palladacyclopentadienyl compounds stabilized by
chelating bisNHCs (1a-b) [16].
The antiproliferative activity against ﬁbroblasts (normal cells)
and different tumor cell lines is compared with that of complexes
containing other spectator ligands (2e6), previously prepared and
described by our research group [12, 17].
The panel of human tumor cell lines tested includes ovarian
carcinomas (A2780 and OVCAR5), lung cancer (A549), malignant
melanoma (A375) and colon cancer (DLD1).
Finally, for the complex 1a we will also propose the results of
speciﬁc biological tests aimed at identifying the main biological
target and deﬁning the most probable mechanism of action.
2. Results and discussion
2.1. Synthesis of palladacyclopentadienyl complexes bearing
chelating bisNHCs (1a-b)
Preliminary tests have highlighted that only the complexes with
benzyl substituents in the wing tip position can be selectivelyScheme 1. Synthesis oobtained. As a matter of fact, when the less cumbersome (i.e.
methyl) or bulkier (i.e. mesityl) substituents are involved, some by-
products, which are difﬁcult to identify and separate, are present in
reaction mixtures in addition to the compounds of interest.
Compounds 1a-b were therefore synthesized by reacting the
complexes Aga-b with the polymeric precursor [PdC4(COOMe)4]n
(Scheme 1), which were prepared according to the published pro-
cedures [18,19].
Transmetallation proceeds in very good yield and the resulting
species were all stable in air and in solution.
The characterization of such compounds was performed by
NMR, IR and elemental analysis. In the 1H spectra (Figs. S1e2) it is
possible to observe:
a) two singlets ascribable to two different pairs of OCH3 groups
within 3 and 4 ppm;
b) an AB system (Jz 15 Hz), between 5 and 6 ppm, ascribable to
the methylene protons of the benzyl substituents;
c) an AB system (J¼ 13.6 Hz), deriving from the protons of the
methylene bridge (for complex 1a) within 6 and 6.5 ppm;
d) two multiplets, between 4 and 5.5 ppm, concerning the
protons of the ethylene bridge (for complex 1b).
In the 13C{H1}-NMR spectra (Figs. S3e4), the signals ascribable
to the two different pairs of C(COOCH3) groups are detected in
addition to the peak of the carbenic carbon at about 180 ppm. A
selection of the bi-dimensional NMR spectra (HSQC and HMBC) is
reported in Figs. S5e6.
Finally, the presence of the carbonyl groups of the cyclo-
palladated fragment is testiﬁed by the intense stretching bands
between 1730 and 1680 cm1 in the IR spectra (Fig. S7).
2.2. X-ray crystal structure determination of 1a
The solid-state structure of derivative 1a was conﬁrmed by X-
ray diffraction. Its crystalline form contains one crystallographically
independent palladium complex showing a square planar coordi-
nation (Fig. 1 and S8, Table S2). Crystal packing of 1a shows hy-
drophobic contacts among neighbour molecules, involving CH$$$p,
and weak intermolecular p$$$p interactions among neighbour
phenyl sidechains of the N-heterocyclic carbene ligands (Fig. 1).
The metal bound ligands adopt conformations equivalent to
those of the complexes with chelating bis(N-heterocyclic carbene)
ligands or palladacyclopentadienyl fragments reported in Table S3.
Both CCDC 1844914 [18] and CCDC 1881566 [12b] show almost
overlapping conformations (R.M.S.D. of common atoms shared by
the models is ~0.60 Å, Fig. S9). Notably, the NHC scaffold varies its
angle with respect to the Pd coordination plane as a function of the
bulkiness of the partner bidentate ligand bound. The mutual angle
between the NHC mean plane and Pd coordination plane increases
from 31.47(1) ((E)-1,2-bis(p-tolylsulfonyl)ethene complex [18]) to
60.62(7) (1a), due to the increased bite angle and steric hindrancef complexes 1a-b.
Fig. 1. Ellipsoid representation of 1a crystals ASU contents (50% probability). Atom
labels in use for Pd coordination sphere are reported.
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steric effect is consistent when 1a is compared with the less bulky
NHC ligand [(1-(2-pyridyl)methylene-3-methyl]imidazolyl-2-ene),
which leads to a less pronounced angle of 56.23(6) (CCDC 1059980
[15c], Fig. S10D). Furthermore, when the NHC imidazolyl ring is free
to rotate (C) it stays almost perpendicular to the palladium coor-
dination sphere (83.48(9) in CCDC 1059981 [15c], Fig. S10C). It can
also be noticed that the carbene conformation in 1a distorts the
palladium coordination sphere pushing the Pd atom out of its co-
ordination plane (distance of Pd from the plane increases from
0.018(1) Å in CCDC 1059980 [15c] or 0.033(1) Å in the ethene
variant [18] to 0.1378(2) Å in 1a).2.3. In vitro antiproliferative activities
The antiproliferative activity of all complexes reported in Chart 1
was evaluated on a panel of different human tumor cell linesTable 1
Effects of the Pd-complexes on the viability of several cancer and normal cells linesa.
Complex IC50 (mM)
A2780 A2780cis OVCAR5
Cisplatin 0.81± 0.06 43± 1 0.84± 0.04
1a 0.039± 0.006 2.8± 0.6 0.30± 0.07
1b 0.46± 0.05 7± 5 0.49± 0.09
2a 46± 11 31± 1 0.13± 0.07
2b 2.6± 0.4 12± 3 7± 2
2c 0.58± 0.03 4.4± 0.3 13± 3
3a 0.33± 0.08 1.3± 0.4 1.2± 0.4
3b 3.9± 0.6 3.4± 0.8 1± 1
3c 1.0± 0.2 0.6± 0.2 3.5± 0.4
3d 2.6± 0.4 3.9± 0.6 13± 2
4a 3.7± 0.2 4.4± 0.9 1.79± 0.06
4b 2.7± 0.2 >100 52± 26
5a 16± 5 >100 >100
5b 98± 49 >100 >100
6 10± 2 28± 3 >100
a Data after 96 h of incubation. Stock solutions in DMSO for all complexes; stock solutio
A2780cis (cisplatin-resistance ovarian cancer cells), A549 (lung cancer cells), A375 (mali(ovarian cancers OVCAR5 and A2780 with its cisplatin resistant
clone A2780cis, lung cancer A549, malignant melanoma A375 and
colon adenocarcinoma DLD1) and MRC-5 normal cells (human ﬁ-
broblasts). Preliminarily, the stability of all compounds was
checked in 1:1 DMSO‑d6/D2O solution (4a-b, 3c-d, and 5a-b and 6)
or DMSO‑d6 (1a-b, 2a-c and 3a-b) by NMR spectroscopy: after 48 h
at room temperature no noticeable degradation was observed.
The half inhibitory concentrations (IC50) induced by palladium
complexes are summarized in Table 1 together with the corre-
sponding values of cisplatin (positive control).
From a ﬁrst analysis of the data, it is evident that a good number
of the tested complexes show a remarkable cytotoxicity against
tumor cell lines, often better than cisplatin, whereas they proved
almost inactive toward the MRC-5 normal cells (IC50> 100 mM),
with the only exceptions of 3a and 3c.
In more detail, it is possible to observe that: a) all complexes
bearing at least one N-heterocyclic carbene ligand (1e4) are
signiﬁcantly active against ovarian cancer and malignant mela-
noma cell lines. Complexes 1a and 1b, (with the chelating bis-NHCs
ligands) are the most efﬁcient species, with IC50 values always
lower than cisplatin; b) all complexes coordinating at least one
monodentate N-heterocyclic carbene (2 and 3 with the only
exception of 3b) show a remarkable cytotoxicity towards DLD1
colon adenocarcinoma cells. Among them, compound 2a presents
an IC50 value about 200 times lower than cisplatin; c) the com-
plexes with mixed NHC and isocyanide or phosphane ligands (3)
exhibit a marked antiproliferative activity versus A549 lung cancer,
with compounds 3b and 3d standing out for their particularly low
IC50 values; d) the palladacyclopentadienyl complexes with
chelating phosphoquinoline or thioquinoline/thiopyridine ligands
are poorly active or inactive toward all investigated cancer cell
lines.
These results highlight that in the group of examined com-
pounds it is always possible to get one or more complexes with a
marked and selective antiproliferative activity against one of the
speciﬁc cancer cell lines investigated. The presence of at least one
N-heterocyclic carbene as ancillary ligand is a necessary requisite
for obtaining this result.
2.4. Reactivity of complexes with GSH
The stability of palladacyclopentadienyl derivatives in the
presence of the biological reductant thiol glutathione (GSH) was
also examined. The tests carried out in DMSO‑d6 or DMSO‑d6/D2OA549 A375 DLD1 MRC-5
6± 3 4.7± 0.4 19± 4 14± 1
>100 0.3± 0.1 >100 >100
>100 2.5± 0.7 >100 >100
>100 19± 16 0.10± 0.09 >100
>100 9± 5 7± 1 >100
>100 10.2± 0.1 34± 15 >100
17± 9 4.4± 0.3 4.7± 0.9 4.7± 0.2
0.05± 0.02 29± 7 >100 >100
2.8± 0.2 5.6± 0.5 5.2± 0.7 4.8± 0.2
0.24± 0.09 4.9± 0.9 7± 2 >100
>100 2± 2 >100 >100
>100 24± 9 >100 >100
>100 37± 3 >100 >100
>100 >100 >100 >100
>100 >100 >100 >100
ns in H2O for cisplatin. A2780 and OVCAR5 (cisplatin-sensitive ovarian cancer cells),
gnant melanoma cells), DLD1 (colon cancer cells), MRC-5 (normal lung ﬁbroblasts).
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each complex were followed by 1H NMR spectroscopy. It was
observed that: a) the complexes containing a chelating or two
monodentate carbene ligands (1e2), as well as the mixed NHC/DIC
derivatives (3c-d), were stable since no signiﬁcant changes of their
spectra had been recorded for 48 h; b) in the mixed NHC/PPh3 and
phosphoquinoline complexes (3a-b and 5a respectively) the
phosphine ligands were completely released in solution within
24 h and promptly converted into the respective phosphine oxides;
c) the complexes coordinating NHC-thioether (4a) and NHC-
pyridine (4b) underwent the labile arm opening immediately af-
ter addition of GSH: the system did not evolve further and the
carbene remained ﬁrmly anchored to the metal centre; d) in the
complexes bearing thioquinoline (5b) and thiopyridine (6) the
bidentate ligands were quickly replaced by glutathione.2.5. Biological activity
Complex 1a was selected for mechanistic studies since it is the
most potent on ovarian cancer cell lines with no activity on normal
cells. To strengthen the data, the biological experiments were car-
ried out by a kinetic analysis at different timepoints. With this
approach it is possible to determine the primary biological effects
generated directly by the palladium compound.
One of the possible mechanisms related to organometallic
anticancer compounds involves an interaction with DNA and its
consequent damage [20]. To test this mechanism, as a sensitive
marker for DNA double-strand breaks, the phosphorylation of
Ser139 of Histone H2A.X was evaluated. After DNA damage, the
phosphorylation at Ser139 helps to recruit the DNA repair machineFig. 2. Immunoﬂuorescence analysis shows that compound 1a induces DNA damage in the
was counterstained with DAPI (Blue). Arrows indicate nuclear foci of Ser139-Histone H2A.X.
interpretation of the references to colour in this ﬁgure legend, the reader is referred to theand apoptotic proteins to dispatch their function [21].
Cells were treatedwith 40, 80, 320 nM of complex 1a for 3, 6 and
12 h. As shown in Fig. 2, after 3 h the phosphorylation of Ser139-
Histone H2A.X starts to accumulate in the nucleus (dotted green,
arrows). The complex was active already at 40 nM, which corre-
sponds to the IC50 value. In the immunoﬂuorescence images, it
appears as foci in the nucleus. Cisplatin was utilized as positive
control at 10 mM.
DNA integrity was analyzed by ﬂow cytometry. SubG1 fraction
was considered as marker of DNA fragmentation. As clearly
observable in Fig. 3, the subG1 fraction of cells treated with com-
pound 1a is dose and time dependent.
At molecular level, cells could activate the apoptotic pathway by
inducing the release of cytochrome C, a conserved electron-
transport protein which is part of the respiratory chain of mito-
chondria. This early event was studied by immunoﬂuorescence.
Cells were treated as in Fig. 4.
After 6e12 h, A2780 cells treated with 1a release cytochrome C
frommitochondria to cytoplasm and appear as diffuse cytoplasmic
staining pattern (Fig. 4). After the release of cytochrome C, cells
activate the caspase cascade to induce apoptosis [22]. The induction
of caspase 3/7 was assessed at different time points and concen-
trations of compound 1a as shown in immunoﬂuorescence exper-
iments (Fig. 5). Starting from 40 nM of complex, cells displayed a
high level of caspase 3/7 compared to untreated cells.3. Conclusions
In this paper, we have described the synthesis and the complete
structural characterization of novel palladacyclopentadienylA2780 cell line. Cells were incubated with Ser139-Histone H2A.X (green) and nucleus
NT, cells incubated with a secondary antibody only. Images were acquired at 20. (For
Web version of this article.)
Fig. 3. A2780 cells were treated as indicated and analyzed by propidium iodide staining. The concentration of complex 1a was nM and cisplatin 10 mM. Ctr cells were untreated.
Histograms showed the average and standard deviation of two independent experiments. Y axis indicates the percentage of cells in sub G1.
Fig. 4. Immunoﬂuorescence analysis demonstrates the release of cytochrome C in the cytoplasm. Cells were probed with cytochrome C antibody (green) and the nucleus was
stained with DAPI (blue). NT cells incubated with secondary antibody only. Images were taken at 20. Boxed indicated zoomed cells. Arrows highlight cytochrome C release in the
cytoplasm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Fig. 5. A2780 cells were treated as indicated and the activity of caspase 3/7 was
measured. Complex 1a induced caspase 3/7 activation starting from low concentra-
tions (40 nM).
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anti-proliferative activities of these new compounds and those of
other palladacyclopentadienyl complexeswith different supporting
ligands, previously prepared by our group, were systematically
tested on different human tumor cell lines. The analysis of the re-
sults has shown that the combination of a palladacyclopentadienyl
organometallic function with at least one NHC ligand assures a
good cytotoxicity, sometimes signiﬁcantly higher than cisplatin,
against many cancer cell lines. Moreover, these derivatives are
almost inactive toward normal MRC-5 cells. One of the most
intriguing results concerns the bis-NHC derivative 1a, which ex-
hibits a particularly high activity against all ovarian cancer cell
lines, matching (or improving) the results of the best palladium
complexes reported in the literature [7c,e]. Furthermore, this
complex is stable in the presence of an excess of GSH and could
reach unaltered its potential bio-target, thereby behaving as an
authentic structural compound.
Platinum based therapy is the ﬁrst line treatment in high grade
serous ovarian cancer. Unfortunately, almost all patients relapseChart 1. Palladacyclopentadienyl cowith a 5-year survival rate of less than 30%. Here, we show that
compound 1a acts primarily on DNA similarly to the platinum
agent, representing a valid alternative to current therapy. Further
experiments are required to understand the exact mechanism of
action but a new hope for patient is on the way.
4. Experimental
All syntheses of complexes were carried out using standard
Schlenk techniques under an atmosphere of dry argon. Dichloro-
methane was ﬁrstly treated with 3Å molecular sieves and then
distilled over P2O5. All the other chemicals were commercially
available grade products and were used as purchased.
Complexes Aga-b [18] and the palladium precursor
[PdC4(COOMe)4]n [19] were synthesized according to published
procedures.
The IR, 1H and 13C{H1}-NMR spectra were recorded on a Perki-
nElmer Spectrum One spectrophotometer and on Bruker 300 or
400 Avance spectrometers, respectively.
Elemental analysis was carried out using an Elemental CHN
"CUBO Micro Vario" analyzer.
4.1. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(1,10-dibenzyl-3,30-methylenediimidazolin-2,20-
diylidene) (1a)
0.0391 g (0.100mmol) of the precursor [PdC4(COOMe)4]n was
dissolved in ca. 10mL of anhydrous CH2Cl2 into a 50mL two necked
ﬂask under inert atmosphere (Ar). The resulting mixture was
treated with 0.0705 g (0.100mmol) of Aga, previously dissolved in
ca. 15mL of anhydrous CH2Cl2, and stirred at RT for ca. 1 h.
The precipitated AgBr was removed by ﬁltration on a millipore
membrane ﬁlter.
Addition of diethylether to the concentrated solution yielded
the complex 1a as a brownish precipitate, which was ﬁltered off on
a gooch and washed with n-pentane.
0.0654 g of 1a was obtained (yield 90%).mplexes studied in this work.
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OCH3), 3.69 (s, 6H, 2 OCH3), 4.98 and 5.60 (AB system, 4H,
J¼ 15.0 Hz, 2 -CH2Ph), 6.00 and 6.49 (AB system, 2H, J¼ 13.6 Hz,
NCH2N), 6.65 (d, 2H, J¼ 1.8 Hz, 2 CHIm), 6.99e7.26 (10H, AreH), 7.32
(d, 2H, J¼ 1.8 Hz, 2 CHIm).
13C{1H NMR (CDCl3, T¼ 298 K, ppm) d: 50.7 (CH3, OCH3), 51.3
(CH3, OCH3), 54.5 (CH2, CH2Ph), 65.5 (CH2, NCH2N), 119.4 (CH,
CHIm), 122.6 (CH, CHIm), 127.8e136.4 (AreC), 145.7 (C, CeCOOCH3),
166.5 (C, COOCH3), 169.7 (C, CeCOOCH3), 177.5 (C, COOCH3), 179.7
(C, carbene).
IR (KBr): nC]O¼ 1733, 1686, nC-O¼ 1194 cm1, 1159 cm1.
Anal. Calcd. for C33H32N4O8Pd: C 55.12, H 4.49, N 7.79. Found: C
55.43, H 4.30, N 7.88.4.2. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(1,10-dibenzyl-3,30-ethylenediimidazolin-2,20-
diylidene) (1b)
Complex 1b was prepared in an analogous manner to that
described for 1a starting from 0.0385 g of [PdC4(COOMe)4]n and
0.0707 g of Agb.
0.0702 g (yield 97%) of 1b was obtained.
1H NMR (400MHz, CDCl3, T¼ 298 K, ppm) d: 3.32 (s, 6H, 2
OCH3), 3.58 (s, 6H, 2 OCH3), 4.35 (m, 2H, NCH2CH2N), 5.02 and 5.07
(AB system, 4H, J¼ 15.4 Hz, 2CH2Ph), 5.33 (m, 2H, NCH2CH2N), 6.56
(d, 2H, J¼ 1.9 Hz, 2 CHIm), 6.93 (d, 2H, J¼ 1.9 Hz, 2 CHIm), 6.86 and
7.10e7.15 (10H, AreH).
13C{1H}NMR (CDCl3, T¼ 298 K, ppm) d: 48.2 (CH2, NCH2CH2N),
50.7 (CH3, OCH3), 51.1 (CH3, OCH3), 54.4 (CH2, CH2Ph), 120.5 (CH,
CHIm), 121.9 (CH, CHIm), 128.0e136.2 (AreC), 144.8 (C, CeCOOCH3),
165.9 (C, COOCH3), 169.9 (C, CeCOOCH3), 177.4 (C, COOCH3), 178.9
(C, carbene).
IR (KBr): nC]O¼ 1691, nC-O¼ 1202 cm1.
Anal. Calcd. for C34H34N4O8Pd: C 55.71, H 4.68, N 7.64. Found: C
55.51, H 4.49, N 7.52.4.3. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)bis(k1-C-([1-benzyl-3-methyl]imidazolyl-2-ene)) (2a)
Complex 2a was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) syn-isomer d: 3.31 (s, 3H,
OCH3), 3.65 (s, 3H, OCH3), 3.95 (s, 3H, NCH3), 5.28 (d, J¼ 15.1 Hz,1H,
NCH2), 5.74 (d, J¼ 15.1 Hz,1H, NCH2), 6.55 (d, J¼ 1.9 Hz,1H, CH]CH
Im), 6.87 (d, J¼ 1.9 Hz, 1H, CH]CH Im), 6.88e6.90 (m, 2H, Ph),
7.20e7.30 (m, 3H, Ph); anti-isomer d: 3.29 (s, 3H, OCH3), 3.55 (s, 3H,
NCH3), 3.64 (s, 3H, OCH3), 5.19 (d, J¼ 15.8 Hz, 1H, NCH2), 5.74 (d,
J¼ 15.8 Hz, 1H, NCH2), 6.71 (s, 2H, CH]CH Im), 6.88e6.90 (m, 2H,
Ph), 7.20e7.30 (m, 3H, Ph).
13C{1H} NMR (CDCl3, T¼ 298 K, ppm) syn-isomer d: 38.1 (CH3,
NCH3), 50.5 (CH3, OCH3), 50.9 (CH3, OCH3), 54.0 (CH2, NCH2), 120.3
(CH, CH]CH Im), 121.9 (CH, CH]CH Im), 128.0 (CH, Ph p-C), 128.1
(CH, Ph o-C), 128.7 (CH, Ph m-C), 135.2 (C, Ph i-C), 143.9 (C, C]C),
165.2 (C, C]O), 169.0 (C, C]C), 176.9 (C, C]O), 181.8 (C, carbene);
anti-isomer d: 37.2 (CH3, NCH3), 50.5 (CH3, OCH3), 50.9 (CH3, OCH3),
54.0 (CH2, NCH2), 120.4 (CH, CH]CH Im), 122.5 (CH, CH]CH Im),
126.7 (CH, Ph o-C),127.9 (CH, Ph p-C), 128.7 (CH, Ph m-C), 135.9 (C,
Ph i-C), 143.7 (C, C]C), 165.1 (C, C]O), 169.0 (C, C]C), 176.9 (C, C]
O), 182.0 (C, carbene). IR (KBr): 1692 cm1 (nCO). Anal. Calcd for
C34H36N4O8Pd: C, 55.55; H, 4.94; N, 7.62. Found C, 55.64; H, 4.92; N,
7.56%.4.4. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)bis(k1-C-([1-(2-pyridyl)methylene-3-methyl]
imidazolyl-2-ene)) (2b)
Complex 2b was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm): syn-isomer d: 3.18 (s, 3H,
OCH3), 3.65 (s, 3H, OCH3), 3.88 (s, 3H, NCH3), 5.27, 5.32 (AB system,
J¼ 16.1 Hz, 2H, NCH2), 6.86 (d, J¼ 1.9 Hz, 1H, CH]CH Im), 6.90 (d,
J¼ 1.9 Hz, 1H, CH]CH Im), 7.12 (ddd, J¼ 7.7, 4.9, 1.0 Hz, 1H, 5-Pyr),
7.24 (d, J¼ 7.7 Hz, 1H, 3-Pyr), 7.56 (td, J¼ 7.7, 1.7 Hz, 1H, 4-Pyr), 8.42
(d, J¼ 4.9 Hz, 1H, 6-Pyr); anti-isomer d: 3.25 (s, 3H, OCH3), 3.58 (s,
3H, NCH3), 3.63 (s, 3H, OCH3), 5.32, (d J¼ 16.1 Hz,1H, NCH2), 5.71, (d
J¼ 16.1 Hz, 1H, NCH2), 6.65 (d, J¼ 1.9 Hz, 1H, CH]CH Im), 6.78 (d,
J¼ 1.9 Hz, 1H, CH]CH Im), 7.07 (d, J¼ 7.7 Hz, 1H, 3-Pyr), 7.18 (ddd,
J¼ 7.7, 4.9, 1.0 Hz, 1H, 5-Pyr), 7.54 (td, J¼ 7.7, 1.7 Hz, 1H, 4-Pyr), 8.47
(d, J¼ 4.9 Hz, 1H, 6-Pyr).
13C{1H } NMR (CDCl3, T¼ 298 K, ppm) syn-isomer d: 38.0 (CH3,
NCH3), 50.5 (CH3, OCH3), 50.9 (CH3, OCH3), 55.6 (CH2, NCH2), 121.0
(CH, CH]CH Im), 121.9 (CH, CH]CH Im), 122.6 (CH, 5-Pyr), 123.5
(CH, 3-Pyr), 136.8 (CH, 4-Pyr), 144.2 (C, C]C), 149.2 (C, 6-Pyr), 155.0
(CH, 2-Pyr), 165.2 (C, C]O), 169.2 (C, C]C), 176.9 (C, C]O), 181.3 (C,
NCN); anti-isomer d: 37.4 (CH3, NCH3), 50.5 (CH3, OCH3), 50.9 (CH3,
OCH3), 55.6 (CH2, NCH2), 120.6 (CH, CH]CH Im), 122.0 (CH, 3-Pyr),
122.3 (CH, CH]CH Im), 122.7 (CH, 5-Pyr), 136.8 (CH, 4-Pyr), 143.9
(C, C]C), 149.2 (C, 6-Pyr), 155.7 (CH, 2-Pyr), 165.3 (C, C]O), 169.2
(C, C]C), 176.9 (C, C]O), 182.0 (C, carbene). IR (KBr): 1692 cm1
(nCO). Anal. Calcd for C32H34N6O8Pd: C, 52.14; H, 4.65; N, 11.40.
Found C, 52.20; H, 4.56; N, 11.33%.
4.5. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)bis(k1-C-([1-(methylthio)methylene-3-methyl]
imidazolyl-2-ene)) (2c)
Complex 2c was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm): syn-isomer d: 2.10 (s, 3H,
SCH3), 3.31 (s, 3H, OCH3), 3.63 (s, 3H, OCH3), 3.83 (s, 3H, NCH3), 4.94
(d, J¼ 13.8 Hz, 1H, SCH2), 5.09 (d, J¼ 13.9 Hz, 1H, SCH2), 6.92 (d,
J¼ 1.9 Hz, 1H, CH]CH Im), 7.26 (d, J¼ 1.9 Hz, 1H, CH]CH Im); anti-
isomer d: 1.87 (s, 3H, SCH3), 3.30 (s, 3H, OCH3), 3.63 (s, 3H, OCH3),
4.00 (s, 3H, NCH3), 4.94 (d, J¼ 13.9 Hz, 1H, SCH2), 5.26 (d,
J¼ 13.9 Hz, 1H, SCH2), 6.96 (d, J¼ 1.9 Hz, 1H, CH]CH Im), 7.19 (d,
J¼ 1.9 Hz, 1H, CH]CH Im).
13C{1H } NMR (CDCl3, T¼ 298 K, ppm) syn-isomer d: 15.2 (CH3,
SCH3), 38.1 (CH3, NCH3), 50.5 (CH3, OCH3), 50.9 (CH3, OCH3), 53.3
(CH2, SCH2), 119.9 (CH, CH]CH Im), 122.4 (CH, CH]CH Im), 144.3
(C, C]C), 165.1 (C, C]O), 168.5 (C, C]C), 176.7 (C, C]O), 181.3 (C,
carbene). anti-isomer d: 13.9 (CH3, SCH3), 38.3 (CH3, NCH3), 50.5
(CH3, OCH3), 50.9 (CH3, OCH3), 54.0 (CH2, SCH2), 119.7 (CH, CH]CH
Im), 122.7 (CH, CH]CH Im), 144.3 (C, C]C), 165.1 (C, C]O), 168.4
(C, C]C), 176.7 (C, C]O), 181.5 (C, carbene). IR (KBr): 1692 cm1
(nCO). Anal. Calcd for C24H32N4O8PdS2: C, 42.70; H, 4.78; N, 8.30.
Found C, 42.88; H, 4.88; N, 8.39%.
4.6. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(k1-C-([1-(4-methylphenyl)methylene-3-methyl]
imidazolyl-2-ene))(triphenylphosphine) (3a)
Complex 3a was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) d: 2.33 (s, 3H, tolyl-CH3), 2.56
(s, 3H, OCH3), 3.21 (s, 3H, OCH3), 3.33 (s, 3H, NCH3), 3.62 (s, 3H,
OCH3), 3.65 (s, 3H, OCH3), 4.56 (d, J¼ 13.8 Hz, 1H, NeCH2), 5.22 (d,
J¼ 13.8 Hz, 1H, NeCH2), 6.29 (d, J¼ 1.8 Hz, 1H, CH]CH Im), 6.51 (d,
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J¼ 7.9 Hz, 2H, tolyl o-H), 7,29-7.44 (m, 15H, PPh3).
13C{1H } NMR (CDCl3, T¼ 298 K, ppm) d: 21.1 (CH3, tolyl-CH3),
37.0 (CH3, NCH3), 49.8 (CH3, OCH3), 50.7 (CH3, OCH3), 51.0 (CH3,
OCH3), 51.1 (CH3, OCH3), 53.8 (CH2, NCH2), 120.0 (CH, CH]CH Im),
121.5 (CH, CH]CH Im), 129.4 (CH, tolyl o-C), 129.9 (CH, tolyl m-C),
130.6 (C, tolyl i-C),138.3 (C, tolyl p-C),145.5 (C, d, JCP¼ 5.7 Hz, C]C),
148.2 (C, d, JCP¼ 7.5 Hz, C]C), 165.1 (C, d, JCP¼ 9.7 Hz, CO), 166.6
(C,CO), 170.0 (C, C]C), 171.5 (C, C]C), 174.9 (C, d, JCP¼ 4.6 Hz, CO),
175.7 (C, d, JCP¼ 5.1 Hz, CO), 178.9 (C, d, JCP¼ 16.5 Hz, carbene). 31P
{1H } NMR (CDCl3, T¼ 298 K, ppm) d: 27.5. IR (KBr): nC]O ¼ 1695,
1794 cm11 (nCO). Anal. Calcd for C42H41N2O8PPd: C, 60.11; H, 4.92;
N, 3.34. Found C, 60.27; H, 4.84; N, 3.39%.
4.7. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(k1-C-([1-(2-pyridyl)methylene-3-methyl]imidazolyl-
2-ene))(triphenylphosphine) (3b)
Complex 3b was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) d: 2.55 (s, 3H, OCH3), 3.10 (s, 3H,
OCH3), 3.23 (s, 3H, NCH3), 3.63 (s, 3H, OCH3), 3.64 (s, 3H, OCH3),
5.08 (d, J¼ 14.6 Hz, 1H, NCH2), 5.32 (d, J¼ 14.8 Hz, 1H, NCH2), 6.50
(d, J¼ 1.8 Hz, 1H, CH]CH Im), 6.95 (d, J¼ 1.8 Hz, 1H, CH]CH Im),
7.14 (m, 1H, 5-Pyr), 7.22e7.39 (m, 16H, 3-Pyr, PPh), 7.52 (td, J¼ 7.5,
1.6 Hz, 1H, 4-Pyr), 8.28 (d, J¼ 4.7 Hz, 1H, 6-Pyr).
13C {1H} NMR (CDCl3, T¼ 298 K, ppm) d: 36.8 (CH3, NCH3), 49.8
(CH3, OCH3), 50.6 (CH3, OCH3), 51.0 (CH3, OCH3), 51.1 (CH3, OCH3),
55.4 (CH2, NCH2), 121.5 (CH, CH]CH Im), 122.0 (CH, CH]CH Im),
122.8 (CH, 5-Pyr), 124.2 (CH, 3-Pyr), 136.8 (CH, 4-Pyr), 145.2 (C, C]
C), 148.1 (C, C]C), 149.0 (C, 6-Pyr), 154.1 (CH, 2-Pyr), 164.3 (C, C]
O), 165.1 (C, C]C), 166.5 (C, C]O), 174.9 (C, C]C), 175.0 (C, C]O),
175.7 (C, C]O), 179.2 (C, carbene). 31P{1H} NMR (CDCl3, T¼ 298 K,
ppm) d: 27.4 (s, PPh3). IR (KBr): 1697 cm1 (nCO). Anal. Calcd for
C40H38N3O8PPd: C, 58.15; H, 4.64; N, 5.09. Found C, 58.20; H, 4.70;
N, 5.18%.
4.8. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(k1-C-([1-(4-methylphenyl)methylene-3-methyl]
imidazolyl-2-ene))(2-isocyano-1,3-dimethylbenzene) (3c)
Complex 3c was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) d: 2.13 (s, 6H, aryl-CH3), 2.15 (s,
3H, tol-CH3), 3.31 (s, 3H, OCH3), 3.59 (s, 3H, OCH3), 3.65 (s, 3H,
OCH3), 3.68 (s, 3H, OCH3), 3.87 (s, 3H, NCH3), 5.09 (d, J¼ 15.0 Hz,1H,
NeCH2), 5.58 (d, J¼ 15.0 Hz, 1H, NeCH2), 6.94e6.97 (m, 4H, CH]
CH Im, tolm-H), 7.06 (d, J¼ 7.6 Hz, 2H, arylm-H), 7.14 (d, J¼ 8.0 Hz,
2H, tol o-H), 7.21 (t, J¼ 7.6 Hz, aryl p-H). 13C{1H} NMR (CDCl3,
T¼ 298 K, ppm) d: 18.6 (CH3, aryl-CH3), 21.3 (CH3, tol-CH3), 38.2
(CH3, NCH3), 51.2 (CH3, OCH3), 51.3 (CH3, OCH3), 51.5 (CH3, OCH3),
51.6 (CH3, OCH3), 54.8 (CH2, NCH2), 121.9 (CH, CH]CH Im), 122.8
(CH, CH]CH Im), 126.5 (C, aryl i-C), 128.3 (CH, arylm-C), 128.4 (CH,
tol o-C), 129.7 (CH, tol m-C), 129.9 (CH, aryl p-C), 133.3 (C, tol i-C),
135.5 (C, aryl o-C), 138.3 (C, tol p-C), 145.9 (C, C]C), 146.7 (C, C]C),
150.5 (C,CN), 164.8 (C, CO), 165.6 (C,CO), 166.6 (C, C]C), 166.9 (C,
C]C), 175.7 (C, CO), 176.5 (C, CO), 178.4 (C, carbene). IR (KBr):
nCO¼ 1697; nCN¼ 2174 cm1. Anal. Calcd for C33H35N3O8Pd: C,
55.98; H, 4.98; N, 5.93. Found C, 55.88; H, 4.88; N, 5.98%.
4.9. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(k1-C-([1-(2-pyridyl)methylene-3-methyl]imidazolyl-
2-ene))(2-isocyano-1,3-dimethylbenzene) (3d)
Complex 3d was synthesized according to published protocol[15c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) d: 2.10 (s, 6H, aryl-CH3), 3.29 (s,
3H, OCH3), 3.61 (s, 3H, OCH3), 3.66 (s, 3H, OCH3), 3.69 (s, 3H, OCH3),
3.86 (s, 3H, NCH3), 5.22 (d, J¼ 14.8 Hz, 1H, NCH2), 5.65 (d,
J¼ 14.8 Hz, 1H, NCH2), 6.97 (d, J¼ 1.8 Hz, 1H, CH]CH Im), 7.01 (m,
1H, 5-Pyr,), 7.04 (d, J¼ 7.8 Hz, 2H, aryl m-H), 7.20 (d, J¼ 7.8 Hz, 1H
aryl p-H), 7.21 (d, J¼ 1.8 Hz, 1H, CH]CH Im), 7.60e7.63 (m, 2H, 3-
Pyr, 4-Pyr), 8.28 (d, J¼ 4.8 Hz, 1H, 6-Pyr).
13C{1H} NMR (CDCl3, T¼ 298 K, ppm) d: 18.1 (CH3, Ar-CH3), 37.8
(CH3, NCH3), 50.7 (CH3, OCH3), 50.8 (CH3, OCH3), 51.1 (CH3, OCH3),
51.2 (CH3, OCH3), 55.9 (CH2, NCH2), 122.0 (CH, CH]CH Im), 122.5
(CH, 5-Pyr), 122.8 (CH, CH]CH Im), 123.9 (CH, 3-Pyr), 126.7 (C, aryl
i-C), 127.8 (CH, aryl m-C), 129.5 (CH, aryl p-C), 135.1 (C, aryl o-C),
136.9 (CH, 4-Pyr), 145.3 (C, C]C), 146.3 (C, C]C), 149.3 (C, 6-Pyr),
155.1 (CH, 2-Pyr), 164.4 (C, C]O), 165.1 (C, C]O), 166.2 (C, C]C),
166.3 (C, C]C), 175.2 (C, C]O),176.1 (C, C]O),177.8 (C, carbene). IR
(KBr): 1697 cm1 (nCO); 2174 cm1 (nCN). Anal. Calcd for
C31H32N4O8Pd: C, 53.57; H, 4.64; N, 8.06. Found C, 53.64; H, 4.56; N,
8.12%.4.10. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)([1-(metylthio)methylene-3-(2,4,6-trimethyl)]
imidazolyl-2-ene)(4a)
Complex 4a was synthesized according to published protocol
[15c] (see Supplementary Material).
1HNMR (CDCl3, T¼ 298 K, ppm) d: 2.28 (bs, 6H, o-aryl-CH3), 2.34
(s, 3H, p-aryl-CH3), 2.37 (s, 3H, SeCH3), 3.13 (s, 3H, OeCH3), 3.56 (s,
3H, OeCH3), 3.59 (s, 3H, OeCH3), 3.70 (s, 3H, OeCH3), 5.05 (bs, 2H,
CH2S), 6.89 (d, J¼ 1.9 Hz, 1H, CH]CH Im) 7.02 (bs, 2H, m-aryl-H),
7.36 (d, J¼ 1.9 Hz, 1H, CH]CH Im).
13C {1H} NMR (CDCl3, T¼ 298 K, ppm) d: 18.2 (CH3, p-mesityl-
CH3), 19.4 (CH3, o-mesityl-CH3), 20.9 (CH3, SeCH3), 50.9 (CH3,
OeCH3), 51.1 (CH3, OeCH3), 51.2 (CH3, OeCH3), 51.3 (CH3, OeCH3),
55.3 (CH2, SCH2), 120.0 (CH, CH]CH Im), 129.7 (CH,m-mesityl-CH);
134.1(C, i-mesityl-C); 135.2 (C, o-mesityl-C); 143.8 (C, C]C), 151.8
(C, C]C), 154.4 (C, C]C), 163.6 (C, CO), 166.6 (C, CO), 172.1 (C, CO),
175.8 (C, C]C), 176.1 (C, CO),186.0 (C, carbene). IR (KBr): 1695 cm1
(nCO). Anal. Calcd for C26H30N2O8PdS: C, 49.02; H, 4.75; N, 4.40.
Found C, 49.12; H, 4.82; N, 4.36%.4.11. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)([1-(2-pyridyl)methylene-3-(2,4,6-trimethyl)]
imidazolyl-2-ene)(4b)
Complex 4b was synthesized according to published protocol
[15c] (see Supplementary Material).
1H NMR (CD2Cl2, T¼ 298 K, ppm) d: 2.21 (bs, 6H, o-mesityl-CH3),
2.37 (s, 3H, p-mesityl-CH3), 3.24 (s, 3H, OCH3), 3.35 (s, 3H, OCH3),
3.55 (s, 3H, OCH3), 3.56 (s, 3H, OCH3), 5.17 (bs, 1H, NCH2), 5.99 (bs,
1H, NCH2), 6.86 (d, J¼ 1.9 Hz, 1H, CH]CH Im), 7.03 (s, 2H, m-
mesityl-H), 7.25 (d, J¼ 1.9 Hz,1H, CH]CH Im), 7.42 (ddd, J¼ 7.7, 4.6,
1.3 Hz, 1H, 5-Pyr); 7.60 (d, J¼ 7.7 Hz, 1H, 3-Pyr); 7.89 (td, J¼ 7.6,
1.7 Hz, 1H, 4-Pyr), 8.64 (d, J¼ 4.6 Hz, 1H, 6- Pyr). 13C {1H } NMR
(CD2Cl2, T¼ 298 K, ppm) d: 19.3 (CH3, o-mesityl), 20.6 (CH3, p-
mesityl), 50.0 (CH3, COOCH3), 50.8 (CH3, COOCH3), 50.9 (CH3,
COOCH3), 51.0 (CH3, COOCH3), 56.3 (CH2, CH2-Pyr), 120.5 (CH, CH]
CH Im), 123.6 (CH, CH]CH Im), 123.9 (CH, 3-Pyr), 124.4 (CH, 5-Pyr),
129.5 (CH, m-mesityl), 134.0 (C, o-mesityl), 134.8 (C, i-mesityl),
138.3 (C, C]C), 138.8 (CH, 4-Pyr), 140.2 (C, p-mesityl), 149.0 (C, C]
C), 152.8 (CH, 6-Pyr), 153.9 (C, C]C), 154.4 (C, 2-Pyr), 163.4 (C, CO),
166.0 (C, CO), 173.4 (C, CO), 174.8 (C, CO), 178.3 (C, C]C), 183.0 (C,
carbene). IR (KBr): 1700 cm1 (nCO). Anal. Calcd for C30H31N3O8Pd:
C, 53.94; H, 4.68; N, 6.29. Found C, 53.84; H, 4.64; N, 6.36%.
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palladium(II)(8-(diphenylphosphino)quinoline) (5a)
Complex 5a was synthesized according to published protocol
[17b] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) d: 2.77 (s, 3H, OCH3), 3.64 (s,
3H, OCH3), 3.71 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 7.39e7.61 (m, 8H,
H3, Ph), 7.64 (ddd, 1H, J¼ 7.7, 7.2, 1.2 Hz, H6), 7.66e7.77 (m, 4H, H5,
Ph), 7.98 (d, 1H, J¼ 7.9 Hz, H7), 8.37 (dt, 1H, J¼ 8.5, 1.4 Hz, H4), 9.06
(dd, 1H, J¼ 5.0, 1.4 Hz, H2).
31P{1H } NMR (CDCl3, T¼ 298 K, ppm) d: 33.4.
13C{1H }NMR (CDCl3, T¼ 298 K, ppm) d: 50.5 (CH3, OCH3), 50.9
(CH3, OCH3), 51.2 (CH3, OCH3), 51.3 (CH3, OCH3),122.6 (CH, C3),127.8
(d, CH, JCP¼ 5.5 Hz, C6), 129.3 (d, C, JCP¼ 7.8 Hz, C10), 131.1 (CH, C5),
135.9 (d, C, JCP¼ 41.7 Hz, C8), 136.1 (CH, C7), 139.0 (CH, C4), 143.2 (C,
C]C), 150.1 (C, C]C), 150.9 (d, C, JCP¼ 21.6 Hz, C9), 154.9 (CH, C2),
157.2 (d, C, JCP¼ 7.5 Hz, C]C), 164.1 (C, C]O), 165.3 (C, C]O), 173.1
(d, C, JCP¼ 8.0 Hz, C]O), 175.4 (d, C, JCP¼ 7.4 Hz, C]O), 176.7 (C, C]
C).
Anal. Calcd for C33H28NO8PPd: C 56.30, H 4.01, N 1.99. Found: C
56.41, H 4.18, N 1.87.
4.13. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(8-(methylthio)quinoline) (5b)
Complex 5b was synthesized according to published protocol
[17a] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm) d: 2.87 (s, 3H, SCH3), 3.72 (s, 3H,
OCH3), 3.74 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 7.63
(dd, 1H, J¼ 8.3, 5.1 Hz, H3), 7.73 (dd, 1H, J¼ 8.2, 7.3 Hz, H6), 8.01 (d,
1H, J¼ 8.2, 1.3 Hz, H5), 8.11 (dd, 1H, J¼ 7.3, 1.3 Hz, H7), 8.46 (dd, 1H,
J¼ 8.3, 1.5 Hz, H4), 9.00 (dd, 1H, J¼ 5.1, 1.5 Hz, H2).
13C{1H}NMR (CDCl3, T¼ 298 K, ppm) d: 27.5 (CH3, SCH3), 52.1
(CH3, OCH3), 51.2 (CH3, OCH3), 51.4 (CH3, OCH3), 51.4 (CH3, OCH3),
122.9 (CH, C3), 128.3 (CH, C6), 130.3 (C, C10), 130.9 (CH, C5), 131.9 (C,
C8), 136.4 (CH, C7), 139.9 (CH, C4), 143.8 (C, C]C), 148.7 (C, C]C),
149.0 (C, C9), 154.3 (CH, C2), 158.6 (C, C]C),163.8 (C, C]O),164.8 (C,
C]O), 169.2 (C, C]C), 173.2 (C, C]O), 174.1 (C, C]O).
IR (KBr): nC]O 1712, 1689 cm1.
Anal. Calcd. for C22H21NO8PdS: C 46.69, H 3.74, N 2.48. Found: C
46.81, H 3.62, N 2.33.
4.14. Synthesis of (1,2,3,4-tetrakis(carbomethoxy)-1,3-pentadienyl)
palladium(II)(2-((methylthio)methyl)pyridine) (6)
Complex 6 was synthesized according to published protocol
[17c] (see Supplementary Material).
1H NMR (CDCl3, T¼ 298 K, ppm): 2.24 (s, 3H, SeCH3), 3.65 (s, 3H,
COOCH3), 3.70 (s, 3H, COOCH3), 3.72 (s, 6H, COOCH3), 4.11 (s, 2H,
pyr-CH2S), 7.41 (td, 1H, H5 pyr, J1¼7.5 Hz, J2¼1.4 Hz), 7.5 (d, 1H, H3
pyr, J¼ 7.7 Hz), 7.88 (td,1H, H4 pyr, J1¼7.5 Hz, J2¼1.7 Hz), 8.65 (dd,
1H, H6 pyr, J¼ 5.6 Hz). 13C NMR (CDCl3, T¼ 298 K, ppm): 18.6
(SeCH3), 43.4 (pyr-CH2-S), 51.5 (COOCH3), 51.8 (COOCH3), 51.9
(COOCH3), 124.7 (C5 pyr), 125.0 (C3 pyr), 139.7 (C4 pyr), 152.5 (C6
pyr), 160.0 (C2 pyr), 144.4 (C]C), 149.0 (C]C), 158.1 (C]C), 169.2
(C]C), 164.1 (COOCH3), 165.3 (COOCH3), 173.7 (COOCH3), 173.9
(COOCH3). Anal. Calcd for C19H21NO8PdS: C 43.07, H 3.99, N 2.64.
Found: C 42.98, H 3.96, N 2.59.
4.15. Crystal structure determination
The crystal data of 1a were collected at 100 K at the XRD1
beamline of the Elettra Synchrotron, Trieste (Italy) [23], using a
monochromatic wavelength of 0.700 Å. The data sets were inte-
grated and corrected for Lorentz, absorption and polarizationeffects with the XDS package [24]. The structures were solved by
direct methods using SHELXT program [25] and reﬁned using
fullmatrix leastsquares implemented in SHELXL2018/3 [26].
Thermal motions for all nonhydrogen atoms were treated aniso-
tropically and hydrogens have been included on calculated posi-
tions, riding on their carrier atoms. Geometric and thermal
restraints (DFIX, DANG and SIMU) were applied to ligands disor-
dered sidechains. No solvent molecules were found in the crystal
packing. The Coot programwas used for structure building [27]. The
crystal data are given in Table S1. Pictures were prepared using
Ortep3 [28] and Pymol [29] softwares.
Crystallographic data has been deposited at the Cambridge
Crystallographic Data Centre and allocated the deposition number
CCDC 1911788. These data can be obtained free of charge via
https://www.ccdc.cam.ac.uk/structures.
4.16. Cell viability assays
Cells were grown in accordance with the supplier and main-
tained at 37 C in a humidiﬁed atmosphere of 5% carbon dioxide.
Five hundred cells were plated in 96 wells and grown for 96 h. Cell
viability was measured with CellTiter glow assay (Promega, Madi-
son, WI, USA) with a Tecan M1000 instrument. IC50 values were
calculated from logistical dose response curves. Averages were
obtained from triplicates and error bars are standard deviations.
4.17. Immunoﬂuorescence microscopy analyses
Cells were seeded at a density of 2 105 cells/mL on coverslip
glass (pretreated with poly-D-Lysine, 1 mg/mL) inserted in 6-well
plates. After overnight culture at 37 C and 5% CO2, cells were
treated with different concentrations of compound 1a (40, 80,
320 nm or 1 mM) or cisplatin (10 mM) for 3, 6, and 12 h. Cells were
ﬁxed in 4% paraformaldehyde/PBS (20min, RT), permeabilizedwith
0.3% Triton X-100/PBS (15min, RT) and blocked in 8% BSA/PBS (1 h,
RT). Cells were stained with mouse monoclonal anti-phospho-
histone pS139H2A.X antibody (1:100 dilution in 1% BSA/PBS, at
4 C, ON) or with mouse monoclonal anti-cytochrome c antibody
(1:100 dilution in 1% BSA/PBS, at 4 C, ON) which were obtained
respectively from Millipore (Cat. # 05e636; Burlington, MA, USA)
and Cell Signaling Technology (Cat. # 12963; Danvers, MA, USA),
and labeled with secondary antibodies (Alexa Fluor® 488 dye,
1:1000 dilution, RT, 2 h) obtained from Cell Signaling Technology
(Cat. # 4408; Danvers, MA, US). To visualize DNA, cells were stained
with DAPI 1mg/mL (1:1000 dilution in PBS, at 4 C, 1min). Cells
were washed three times with 1 PBS after all incubations. All the
coverslips were mounted in ﬂuorSave™ reagent (Cat. # 345789;
Millipore: Burlington, MA, USA), the cells were examined with a
Nikon Eclipse Ti ﬂuorescence microscope, and the images were
analyzed with NIS Elements software version 3.0 (Nikon: Shina-
gawa, Tokyo, Japan).
4.18. Flow cytometry analysis
Cells were seeded at a density of 105 cells/mL on 10mL plates.
After incubation overnight at 37 C in 5% CO2, cells were treated
with different concentrations of compound 1a (40, 80 or 320 nM)
or cisplatin (10 mM) for 24, 48 and 96 h. Cells were collected by
trypsinization and centrifugation for each time point. After a
washing step with 1 PBS, the pellet was resuspended in 1mL of
PBS and 9mL of cold 70% EtOH while vortexing. 106 cells were
incubated in 70% EtOH at 4 C for at least 2 h. Cells were re-collected
by centrifugation and suspended in 300 ml of the propidium iodide/
RNAse A fresh solution (PBS, 10mg/mL RNase A, 1mg/mL propi-
dium iodide). Cells were incubated at 37 C for 60min then
T. Scattolin et al. / European Journal of Medicinal Chemistry 179 (2019) 325e334334analyzed by a FACSCalibur ﬂow cytometer (BD Biosciences, Franklin
Lakes, NJ, USA). Populations of cells at different phases of cell cycle
were analyzed with the ModFit LT4.0 software.
4.19. Caspase-3/7 activity detection
The activity of caspase-3/7 was determined by Caspase-Glo™ 3/
7 Assay (Cat. #G8091; Promega: Madison, WI, USA). Cells were
seeded at a density of 105 cells/mL on 6-well plates. After incuba-
tion overnight at 37 C in 5% CO2, cells were treated with different
concentrations of compound 1a (40, 80, 320 nM or 1 mM) or
cisplatin (10 mM) for 3, 12, and 24 h. Cells were collected by tryp-
sinization and centrifugation. Cells were lysed in a buffer contain-
ing Tris HCl 1M pH 8, NaCl 5M,10% glycerol, 1% NP-40, EDTA 0.5M,
sodium orthovanadate 2mM, sodium ﬂuoride 5mM and EDTA-free
protease inhibitors 25 (Cat. # 04693132001, Roche: Basel,
Switzerland). The cellular protein content was quantiﬁed with an
Eppendorf BioPhotometer (Hamburg, Germany). The assay was
performed with 40 mg of protein extracts in 1:1 ratio of Caspase-
Glo® 3/7 reagent in triplicate in 96-well plate. The assay was
incubated at RT for 30min. Luminescence was recorded using a
Tecan M1000 PRO instrument (M€annedorf, Zürich, Switzerland).
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